文献速递泌尿生殖与妇科肿瘤放疗

前列腺腺癌剂量递增:一项3期单中心随机临床试验的长期结局更新

Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-03-02

1993至1998年,301例经活检证实为临床T1b-T3期前列腺腺癌、任何前列腺特异抗原水平、任何Gleason评分的患者随机接受70 Gy/35次或78 Gy/39次光子放疗,均采用四野盒式技术且未行雄激素剥夺治疗。中位随访14.3年,78 Gy组15年生化或临床失败累积发生率、远处转移累积发生率和前列腺癌特异性死亡累积发生率均低于70 Gy组,总生存无差异;78 Gy组挽救治疗比例更低。

要点

  • 15年生化或临床失败累积发生率78 Gy组12.0%低于70 Gy组18.9%(sHR 0.61;95%CI 0.38-0.98;Fine-Gray P=.042)。
  • 15年前列腺癌特异性死亡累积发生率78 Gy组3.2%低于70 Gy组6.2%(sHR 0.52;95%CI 0.27-0.98;Fine-Gray P=.045)。
  • 总生存两组无差异(HR 1.10;95%CI 0.84-1.45;log rank P=.469),78 Gy组挽救治疗比例21.9%低于70 Gy组38.7%(P=.002)。

核心结论

  • 剂量从70 Gy递增至78 Gy(增加8 Gy)持续改善生化与临床失败,并降低挽救治疗率和前列腺癌特异性死亡,但未改善总生存。
  • 长期随访显示放射治疗野内潜在实体瘤第二恶性肿瘤发生率低。

研究设计与样本

  • 1993至1998年开展的3期单中心随机临床试验,301例经活检证实为临床T1b-T3期前列腺腺癌、任何前列腺特异抗原水平、任何Gleason评分。
  • 随机分入70 Gy/35次组与78 Gy/39次组,采用四野盒式技术光子放疗,未行雄激素剥夺治疗;主要终点把握度设定为检测生化或临床失败15%的差异。

主要发现

  • 中位随访14.3年,15年生化或临床失败累积发生率70 Gy组18.9% vs 78 Gy组12.0%(sHR 0.61;95%CI 0.38-0.98;Fine-Gray P=.042)。
  • 15年远处转移累积发生率70 Gy组3.4% vs 78 Gy组1.1%(sHR 0.33;95%CI 0.13-0.82;Fine-Gray P=.018)。
  • 15年前列腺癌特异性死亡累积发生率70 Gy组6.2% vs 78 Gy组3.2%(sHR 0.52;95%CI 0.27-0.98;Fine-Gray P=.045)。
  • 总生存两组无差异(HR 1.10;95%CI 0.84-1.45;log rank P=.469),其他原因生存两组无差异(sHR 1.33;95%CI 0.99-1.79;Fine-Gray P=.061)。
  • 挽救治疗70 Gy组38.7% vs 78 Gy组21.9%(P=.002);放射治疗野内第二实体恶性肿瘤发生率2.3%(膀胱1例、直肠6例),两组间无显著差异。

关键数值与推荐

  • 剂量递增方案为70 Gy/35次 vs 78 Gy/39次光子放疗,采用四野盒式技术,未行雄激素剥夺治疗。
  • 15年生化或临床失败:70 Gy组18.9% vs 78 Gy组12.0%(sHR 0.61;95%CI 0.38-0.98;Fine-Gray P=.042)。
  • 15年远处转移:70 Gy组3.4% vs 78 Gy组1.1%(sHR 0.33;95%CI 0.13-0.82;Fine-Gray P=.018)。
  • 15年前列腺癌特异性死亡:70 Gy组6.2% vs 78 Gy组3.2%(sHR 0.52;95%CI 0.27-0.98;Fine-Gray P=.045)。
  • 15年总生存无差异(HR 1.10;95%CI 0.84-1.45;log rank P=.469);挽救治疗70 Gy组38.7% vs 78 Gy组21.9%(P=.002)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the long-term outcomes for prostate adenocarcinoma when escalating radiation dose from 70 Gy to 78 Gy. METHODS AND MATERIALS: Between 1993 and 1998, 301 patients with biopsy-proven clinical stage T1b-T3 prostate adenocarcinoma, any prostate-specific antigen level, and any Gleason score were randomized to 70 Gy in 35 fractions versus 78 Gy in 39 fractions of photon radiation therapy using a 4-field box technique without hormone deprivation therapy. The primary outcome was powered to detect a 15% difference in biochemical or clinical failure. Secondary outcomes included survival, prostate cancer mortality, biochemical failure, local failure, nodal failure, distant failure, and secondary malignancy rates. RESULTS: With a median follow-up of 14.3 years, the cumulative incidence of 15-year biochemical or clinical failure was 18.9% versus 12.0% in the 70 Gy versus 78 Gy arms, respectively (subhazard ratio [sHR], 0.61; 95% confidence interval [CI], 0.38-0.98; Fine-Gray P = .042). The 15-year cumulative incidence of distant metastasis was 3.4% versus 1.1%, respectively (sHR, 0.33; 95% CI, 0.13-0.82; Fine-Gray P = .018). The 15-year cumulative incidence of prostate cancer-specific mortality was 6.2% versus 3.2%, respectively, (sHR, 0.52; 95% CI, 0.27-0.98; Fine-Gray P = .045). There were no differences in overall survival (HR, 1.10; 95% CI, 0.84-1.45; log rank P = .469) or other-cause survival (sHR, 1.33; 95% CI, 0.99-1.79; Fine-Gray P = .061). Salvage therapy was more common in the 70 Gy arm, at 38.7% versus 21.9% in the 78 Gy arm (P = .002). There was a 2.3% secondary solid malignancy rate (1 bladder, 6 rectal) within the radiation treatment field, which was not significantly different between treatment arms. CONCLUSIONS: Dose escalation by 8 Gy (78 Gy vs 70 Gy) provided a sustained improvement in biochemical and clinical failure, which translated into lower salvage rates and improved prostate cancer-specific mortality, but not overall survival. Long-term follow-up demonstrated a low incidence of potential solid tumor secondary malignancies.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Pasalic D, Kuban DA, Allen PK, et al. Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2019. PMID: 30836166. doi:10.1016/j.ijrobp.2019.02.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。